Statements (94)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:vaccine
|
| gptkbp:accessories |
global
multiple countries |
| gptkbp:approves |
gptkb:Russia
December 2020 |
| gptkbp:average_temperature |
-18° C
|
| gptkbp:clinical_trial |
over 40,000
multiple countries Phase III published in The Lancet |
| gptkbp:country_of_origin |
gptkb:Russia
|
| gptkbp:developed_by |
Gamaleya Research Institute
|
| gptkbp:distribution |
global
international |
| gptkbp:dosage_form |
2
|
| gptkbp:dose_schedule |
two doses
2 doses |
| gptkbp:doses |
two
|
| gptkbp:effective_date |
approved in multiple countries
|
| https://www.w3.org/2000/01/rdf-schema#label |
Sputnik V
|
| gptkbp:is_effective_against |
91.6%
|
| gptkbp:is_vulnerable_to |
gptkb:virus
gptkb:CORBA gptkb:Sputnik_V gptkb:significant gptkb:complex global ongoing mixed affordable pricing international partnerships emergency use authorization ongoing studies mixed responses August 2020 rapid in several countries rapid development logistical issues post-marketing surveillance government and private investments government and private investment strong immune response against variants collaborations with other countries reduction in COVID-19 cases against severe disease standard refrigeration advancements in vaccine technology addressed through education campaigns conducted in multiple phases important for uptake live attenuated virus monitored post-approval human adenovirus involvement of local health authorities reducing COVID-19 cases |
| gptkbp:manufacturer |
Russian Direct Investment Fund
|
| gptkbp:marketed_as |
Gam-COVID-Vac
|
| gptkbp:origin |
gptkb:Sputnik_satellite
named after the first artificial satellite |
| gptkbp:partnerships |
gptkb:various_countries
|
| gptkbp:platform |
adenoviral vector
|
| gptkbp:production_volume |
millions of doses
|
| gptkbp:publication |
gptkb:Lancet
peer-reviewed studies |
| gptkbp:regulatory_compliance |
multiple countries
in over 70 countries |
| gptkbp:route_of_administration |
intramuscular
|
| gptkbp:safety_features |
generally safe
|
| gptkbp:side_effect |
mild to moderate
|
| gptkbp:targets |
gptkb:COVID-19
|
| gptkbp:type |
viral vector vaccine
|
| gptkbp:vaccine_approval_process |
expedited due to pandemic
|
| gptkbp:vaccine_clinical_data |
submitted to WHO
|
| gptkbp:vaccine_comparative_efficacy |
compared to other vaccines
|
| gptkbp:vaccine_crisis_response |
part of emergency health measures
part of global response to COVID-19. |
| gptkbp:vaccine_distribution_channels |
government and private sectors
|
| gptkbp:vaccine_distribution_strategy |
targeted regions
|
| gptkbp:vaccine_ethical_considerations |
discussed in scientific forums
|
| gptkbp:vaccine_future_research |
exploration of new variants.
|
| gptkbp:vaccine_global_access |
aimed for equitable distribution
|
| gptkbp:vaccine_global_distribution |
cooperation with international organizations
|
| gptkbp:vaccine_global_health_impact |
contribution to pandemic response
|
| gptkbp:vaccine_long_term_studies |
ongoing monitoring of effects
|
| gptkbp:vaccine_mechanism |
induces immune response
|
| gptkbp:vaccine_public_health_strategy |
part of vaccination campaigns
|
| gptkbp:vaccine_public_trust |
building through transparency
|
| gptkbp:vaccine_regulatory_challenges |
faced in some regions
|
| gptkbp:vaccine_regulatory_pathway |
expedited process
|
| gptkbp:vaccine_target_population |
adults
|
| gptkbp:whoapproval |
under evaluation
|
| gptkbp:whoapproval_status |
Emergency Use Listing
|